Lymphact
Évora
About Lymphact
Lymphact is a biopharmaceutical start-up focused on developing innovative personalized medical treatments. Their products and technologies are designed to harness the power of the immune system, the target-specific cellular mechanism which evolved in vertebrates during the last 450 million years, towards a permanent elimination of pathogens. After 5 years of pioneering research and development in this field, they created a new technology platform which can generate autologous and allogeneic cellular immune therapies for clinical applications: DOT-Cells®.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $357.7K
- Funding stage: M&A
- Last round: Seed (Jan 2014)
- Website: lymphact.com
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lymphact-357616 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.